NCT05352321

Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma

Multicenter Randomized Controlled Trial of Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 264 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Through a prospective clinical trial, we intend to combine surgery, induction chemotherapy, target-reduction intensity-modulated radiotherapy and concurrent chemotherapy as an experimental treatment for patients with newly diagnosed resectable nasopharyngeal carcinoma to illuminate whether combined surgery could bring patients better local-regional control and lower adverse reactions.

Conditions

• Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	Gemcitabine	for induction chemotherapy
DRUG	Cisplatin	for induction and concurrent chemotherapy
RADIATION	regular intensity-modulated radiotherapy	in active comparator arm
PROCEDURE	surgery	in experimental arm
RADIATION	Target-reduction intensity-modulated radiotherapy	in experimental arm

Timeline

• Start date: 2022-06-01
• Primary completion: 2025-06-01
• Completion: 2028-06-01
• First posted: 2022-04-28
• Last updated: 2022-07-01

Locations

2 sites across 1 country: China